Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis

Serkin Park, Jinhui Liao, Janice E. Berry, Xin Li, Amy J. Koh, Megan E. Michalski, Matthew R. Eber, Fabiana N. Soki, David Sadler, Ha Sud, Sandra Tisdelle, Stephanie D. Daignault, Jeffrey A. Nemeth, Linda A. Snyder, Thomas J. Wronski, Kenneth J. Pienta, Laurie K. McCauley

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A number of cancers predominantly metastasize to bone, due to its complex microenvironment and multiple types of constitutive cells. Prostate cancer especially has been shown to localize preferentially to bones with higher marrow cellularity. Using an experimental prostate cancer metastasis model, we investigated the effects of cyclophosphamide, a bone marrow-suppressive chemotherapeutic drug, on the development and growth of metastatic tumors in bone. Priming the murine host with cyclophosphamide before intracardiac tumor cell inoculation was found to significantly promote tumor localization and subsequent growth in bone. Shortly after cyclophosphamide treatment, there was an abrupt expansion of myeloid lineage cells in the bone marrow and the peripheral blood, associated with increases in cytokines with myelogenic potential such as C-C chemokine ligand (CCL)2, interleukin (IL)-6, and VEGF-A. More importantly, neutralizing host-derived murine CCL2, but not IL-6, in the premetastatic murine host significantly reduced the prometastatic effects of cyclophosphamide. Together, our findings suggest that bone marrow perturbation by cytotoxic chemotherapy can contribute to bone metastasis via a transient increase in bone marrow myeloid cells and myelogenic cytokines. These changes can be reversed by inhibition of CCL2.

Original languageEnglish
Pages (from-to)2522-2532
Number of pages11
JournalCancer Research
Volume72
Issue number10
DOIs
Publication statusPublished - 2012 May 15
Externally publishedYes

Fingerprint

Cyclophosphamide
Prostatic Neoplasms
Bone Marrow
Neoplasm Metastasis
Bone and Bones
Myeloid Cells
Interleukin-6
Neoplasms
Cytokines
CC Chemokines
Bone Development
Growth and Development
Bone Marrow Cells
Vascular Endothelial Growth Factor A
Ligands
Drug Therapy
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Park, S., Liao, J., Berry, J. E., Li, X., Koh, A. J., Michalski, M. E., ... McCauley, L. K. (2012). Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Research, 72(10), 2522-2532. https://doi.org/10.1158/0008-5472.CAN-11-2928

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. / Park, Serkin; Liao, Jinhui; Berry, Janice E.; Li, Xin; Koh, Amy J.; Michalski, Megan E.; Eber, Matthew R.; Soki, Fabiana N.; Sadler, David; Sud, Ha; Tisdelle, Sandra; Daignault, Stephanie D.; Nemeth, Jeffrey A.; Snyder, Linda A.; Wronski, Thomas J.; Pienta, Kenneth J.; McCauley, Laurie K.

In: Cancer Research, Vol. 72, No. 10, 15.05.2012, p. 2522-2532.

Research output: Contribution to journalArticle

Park, S, Liao, J, Berry, JE, Li, X, Koh, AJ, Michalski, ME, Eber, MR, Soki, FN, Sadler, D, Sud, H, Tisdelle, S, Daignault, SD, Nemeth, JA, Snyder, LA, Wronski, TJ, Pienta, KJ & McCauley, LK 2012, 'Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis', Cancer Research, vol. 72, no. 10, pp. 2522-2532. https://doi.org/10.1158/0008-5472.CAN-11-2928
Park, Serkin ; Liao, Jinhui ; Berry, Janice E. ; Li, Xin ; Koh, Amy J. ; Michalski, Megan E. ; Eber, Matthew R. ; Soki, Fabiana N. ; Sadler, David ; Sud, Ha ; Tisdelle, Sandra ; Daignault, Stephanie D. ; Nemeth, Jeffrey A. ; Snyder, Linda A. ; Wronski, Thomas J. ; Pienta, Kenneth J. ; McCauley, Laurie K. / Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. In: Cancer Research. 2012 ; Vol. 72, No. 10. pp. 2522-2532.
@article{ed8a01fe01f1415bbf716c0581c56ba6,
title = "Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis",
abstract = "A number of cancers predominantly metastasize to bone, due to its complex microenvironment and multiple types of constitutive cells. Prostate cancer especially has been shown to localize preferentially to bones with higher marrow cellularity. Using an experimental prostate cancer metastasis model, we investigated the effects of cyclophosphamide, a bone marrow-suppressive chemotherapeutic drug, on the development and growth of metastatic tumors in bone. Priming the murine host with cyclophosphamide before intracardiac tumor cell inoculation was found to significantly promote tumor localization and subsequent growth in bone. Shortly after cyclophosphamide treatment, there was an abrupt expansion of myeloid lineage cells in the bone marrow and the peripheral blood, associated with increases in cytokines with myelogenic potential such as C-C chemokine ligand (CCL)2, interleukin (IL)-6, and VEGF-A. More importantly, neutralizing host-derived murine CCL2, but not IL-6, in the premetastatic murine host significantly reduced the prometastatic effects of cyclophosphamide. Together, our findings suggest that bone marrow perturbation by cytotoxic chemotherapy can contribute to bone metastasis via a transient increase in bone marrow myeloid cells and myelogenic cytokines. These changes can be reversed by inhibition of CCL2.",
author = "Serkin Park and Jinhui Liao and Berry, {Janice E.} and Xin Li and Koh, {Amy J.} and Michalski, {Megan E.} and Eber, {Matthew R.} and Soki, {Fabiana N.} and David Sadler and Ha Sud and Sandra Tisdelle and Daignault, {Stephanie D.} and Nemeth, {Jeffrey A.} and Snyder, {Linda A.} and Wronski, {Thomas J.} and Pienta, {Kenneth J.} and McCauley, {Laurie K.}",
year = "2012",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-11-2928",
language = "English",
volume = "72",
pages = "2522--2532",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis

AU - Park, Serkin

AU - Liao, Jinhui

AU - Berry, Janice E.

AU - Li, Xin

AU - Koh, Amy J.

AU - Michalski, Megan E.

AU - Eber, Matthew R.

AU - Soki, Fabiana N.

AU - Sadler, David

AU - Sud, Ha

AU - Tisdelle, Sandra

AU - Daignault, Stephanie D.

AU - Nemeth, Jeffrey A.

AU - Snyder, Linda A.

AU - Wronski, Thomas J.

AU - Pienta, Kenneth J.

AU - McCauley, Laurie K.

PY - 2012/5/15

Y1 - 2012/5/15

N2 - A number of cancers predominantly metastasize to bone, due to its complex microenvironment and multiple types of constitutive cells. Prostate cancer especially has been shown to localize preferentially to bones with higher marrow cellularity. Using an experimental prostate cancer metastasis model, we investigated the effects of cyclophosphamide, a bone marrow-suppressive chemotherapeutic drug, on the development and growth of metastatic tumors in bone. Priming the murine host with cyclophosphamide before intracardiac tumor cell inoculation was found to significantly promote tumor localization and subsequent growth in bone. Shortly after cyclophosphamide treatment, there was an abrupt expansion of myeloid lineage cells in the bone marrow and the peripheral blood, associated with increases in cytokines with myelogenic potential such as C-C chemokine ligand (CCL)2, interleukin (IL)-6, and VEGF-A. More importantly, neutralizing host-derived murine CCL2, but not IL-6, in the premetastatic murine host significantly reduced the prometastatic effects of cyclophosphamide. Together, our findings suggest that bone marrow perturbation by cytotoxic chemotherapy can contribute to bone metastasis via a transient increase in bone marrow myeloid cells and myelogenic cytokines. These changes can be reversed by inhibition of CCL2.

AB - A number of cancers predominantly metastasize to bone, due to its complex microenvironment and multiple types of constitutive cells. Prostate cancer especially has been shown to localize preferentially to bones with higher marrow cellularity. Using an experimental prostate cancer metastasis model, we investigated the effects of cyclophosphamide, a bone marrow-suppressive chemotherapeutic drug, on the development and growth of metastatic tumors in bone. Priming the murine host with cyclophosphamide before intracardiac tumor cell inoculation was found to significantly promote tumor localization and subsequent growth in bone. Shortly after cyclophosphamide treatment, there was an abrupt expansion of myeloid lineage cells in the bone marrow and the peripheral blood, associated with increases in cytokines with myelogenic potential such as C-C chemokine ligand (CCL)2, interleukin (IL)-6, and VEGF-A. More importantly, neutralizing host-derived murine CCL2, but not IL-6, in the premetastatic murine host significantly reduced the prometastatic effects of cyclophosphamide. Together, our findings suggest that bone marrow perturbation by cytotoxic chemotherapy can contribute to bone metastasis via a transient increase in bone marrow myeloid cells and myelogenic cytokines. These changes can be reversed by inhibition of CCL2.

UR - http://www.scopus.com/inward/record.url?scp=84861179255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861179255&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2928

DO - 10.1158/0008-5472.CAN-11-2928

M3 - Article

C2 - 22589273

AN - SCOPUS:84861179255

VL - 72

SP - 2522

EP - 2532

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 10

ER -